全文获取类型
收费全文 | 529550篇 |
免费 | 34619篇 |
国内免费 | 665篇 |
专业分类
耳鼻咽喉 | 7100篇 |
儿科学 | 17267篇 |
妇产科学 | 13899篇 |
基础医学 | 87028篇 |
口腔科学 | 15234篇 |
临床医学 | 45645篇 |
内科学 | 97340篇 |
皮肤病学 | 12448篇 |
神经病学 | 37571篇 |
特种医学 | 19009篇 |
外国民族医学 | 63篇 |
外科学 | 79358篇 |
综合类 | 8576篇 |
一般理论 | 124篇 |
预防医学 | 40179篇 |
眼科学 | 12450篇 |
药学 | 41417篇 |
中国医学 | 1047篇 |
肿瘤学 | 29079篇 |
出版年
2018年 | 5451篇 |
2016年 | 4500篇 |
2015年 | 4953篇 |
2014年 | 6649篇 |
2013年 | 10247篇 |
2012年 | 13899篇 |
2011年 | 15277篇 |
2010年 | 8966篇 |
2009年 | 8320篇 |
2008年 | 14538篇 |
2007年 | 15603篇 |
2006年 | 15760篇 |
2005年 | 15138篇 |
2004年 | 14699篇 |
2003年 | 13981篇 |
2002年 | 13794篇 |
2001年 | 24386篇 |
2000年 | 25365篇 |
1999年 | 20892篇 |
1998年 | 5571篇 |
1997年 | 4860篇 |
1996年 | 5156篇 |
1995年 | 4732篇 |
1994年 | 4410篇 |
1992年 | 15945篇 |
1991年 | 16496篇 |
1990年 | 16590篇 |
1989年 | 15980篇 |
1988年 | 14741篇 |
1987年 | 14556篇 |
1986年 | 13752篇 |
1985年 | 13128篇 |
1984年 | 9738篇 |
1983年 | 8338篇 |
1982年 | 4623篇 |
1981年 | 4297篇 |
1979年 | 9490篇 |
1978年 | 6915篇 |
1977年 | 5814篇 |
1976年 | 5647篇 |
1975年 | 6451篇 |
1974年 | 7679篇 |
1973年 | 7191篇 |
1972年 | 7007篇 |
1971年 | 6709篇 |
1970年 | 6204篇 |
1969年 | 5916篇 |
1968年 | 5582篇 |
1967年 | 5032篇 |
1966年 | 4473篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
N. N. Polygalova A. G. Mikhailovskii E. S. Limanskii B. Ya. Syropyatov M. I. Vakhrin 《Pharmaceutical Chemistry Journal》2006,40(3):132-134
A series of 1-alkyl-3,4-dihydroisoquinolines and the related 4-alkyl-1,2-dihydro-benzo[f]isoquinolines was synthesized using
reactions of dialkylbenzylcarbinols and their naphthyl analogs with alkylcyanides. Experiments showed that 1-alkyl-6,7-dimethoxy-3,4-dihydroisoquinolines
typically produce a hypotensive action, while the benzo-annelated structures usually exhibit a hypertensive effects. The most
active compound decreases the arterial pressure in cats by 52 Torr and the effect lasts for about 4 hours.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 3, pp. 15–17, March, 2006. 相似文献
32.
33.
34.
AIMS: To examine the effects of agents that alter potassium adenosine triphosphate (KATP) channel activity in beta-cells on cognitive function and counterregulatory hormone responses during acute hypoglycaemia, given the physiological similarities between the pancreatic beta-cell and the hypothalamic glucose-sensitive neurones (GSN) and the widespread distribution of sulphonylurea receptors in neuronal cells throughout the brain. METHODS: Ten healthy males were studied on four occasions and in random order underwent three stepped hypoglycaemic (plasma glucose aims: 3.4, 2.8, 2.4 mmol/l) and one euglycaemic (plasma glucose aim: 5 mmol/l) insulin clamps. Prior to each hypoglycaemic study, volunteers received either 10 mg glibenclamide, or 5 mg/kg diazoxide or placebo orally. Cognitive function, symptom scores and counterregulatory hormone responses were measured at each glycaemic level. RESULTS: There was no statistically significant effect of either drug on the symptoms generated or the counterregulatory hormonal response during hypoglycaemia. However, cognitive function was better preserved during hypoglycaemia in the glibenclamide-treated arm, particularly four-choice reaction time which deteriorated at a plasma glucose 2.5 mmol/l compared with 3.0 mmol/l with diazoxide (P = 0.015) and 2.9 mmol/l with placebo (P = 0.114). CONCLUSIONS: Single doses of pharmacological agents which alter membrane KATP channel activity do not affect the counterregulatory response to hypoglycaemia but may modify cognitive function during cerebral glucopenia. The unexpected effects of glibenclamide on cortical function suggest a novel action of sulphonylureas that warrants further investigation. 相似文献
35.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
36.
S. V. Terent’eva E. N. Komarova T. N. Sapozhnikova A. T. Teplyakov E. A. Ivanovskaya T. I. Andreeva 《Pharmaceutical Chemistry Journal》2006,40(12):694-696
A rapid procedure for determining angiotensin II in the blood by inverse voltammetry using a TA-2 device (Tekhnoanalit Company,
Tomsk) with a graphite electrode has been developed. The results of analyses using the proposed technique agree with the clinical
data. The rapid analytical procedure favors optimization of cardiotropic drug therapy.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 12, pp. 54–56, December, 2006. 相似文献
37.
38.
G. Kahlmeter D. F. J. Brown F. W. Goldstein A. P. MacGowan J. W. Mouton I. Odenholt A. Rodloff C-J. Soussy M. Steinbakk F. Soriano O. Stetsiouk 《Clinical microbiology and infection》2006,12(6):501-503
The main objectives of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are to harmonise breakpoints for antimicrobial agents in Europe, and to act as the breakpoint committee for the European Medicines Agency (EMEA) during the registration of new antimicrobial agents. Detailed EUCAST procedures for harmonising and setting breakpoints for antimicrobial agents are available on the EUCAST website. Beginning with the current issue, a series of EUCAST Technical Notes will be published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial agents studied, with the aim of highlighting important background information underlying decisions on breakpoints made by EUCAST. 相似文献
39.
OBJECTIVE: To compare infants' discomfort, nursing-time and caregiver preference, and assess the clinical efficiency (as a secondary outcome) of hood versus facemask nebulization in infants with evolving bronchopulmonary dysplasia (BPD) in the neonatal intensive care unit. STUDY DESIGN: A prospective, open, randomized, controlled crossover clinical trial. In total, 10 infants with BPD who were on inhaled beta-agonist bronchodilators and corticosteroids were randomly assigned to receive their nebulized treatments either by a facemask, or by a hood for 2-3 days, and then crossover to receive the same treatments with the other technique for another 2-3 days. Infants' discomfort, nursing-time, caregiver preference and clinical efficiency were compared. RESULTS: At baseline there was no significant clinical difference between the groups. Nurse-time required for administering the hood nebulization (mean+/-s.e.m.: 1.9+/-0.1 min) was significantly shorter than the time for mask nebulization (12.0+/-0.6 min, P<0.0001). Infants' discomfort score was significantly lower (0.1+/-0.04) for hood versus mask nebulization (2.5+/-0.2, P<0.0001). Nurses and parents unequivocally preferred the hood treatment. During both mask and hood nebulization therapies (2-3 days) clinical efficiency was comparable. While both methods caused an immediate (20 min post) clinical improvement, the immediate respiratory assessment change score was significantly greater for the hood versus the mask nebulization (0.62+/-0.27 versus 0.13+/-0.14, P<0.05). CONCLUSIONS: Nebulization of aerosolized medications in infants with evolving BPD by hood was less time-consuming for caregivers and was much better tolerated by the infants while being at least as effective as the conventional facemask nebulization. 相似文献
40.
Daniel D. Billadeau Subrha Chatterjee Patricia Bramati Raghavakaimal Sreekumar Vijay Shah Karen Hedin Raul Urrutia 《Journal of gastrointestinal cancer》2006,37(4):110-119
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1α, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease. 相似文献